Details for Patent: 8,980,901
✉ Email this page to a colleague
Which drugs does patent 8,980,901 protect, and when does it expire?
Patent 8,980,901 protects ZYDELIG and is included in one NDA.
This patent has forty-six patent family members in twenty countries.
Summary for Patent: 8,980,901
| Title: | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
| Abstract: | Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. Exemplary compounds disclosed in this application are shown below: ##STR00001## |
| Inventor(s): | Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA) |
| Assignee: | Icos Corporation (Foster City, CA) |
| Application Number: | 14/049,163 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
More… ↓ |
Drugs Protected by US Patent 8,980,901
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-001 | Jul 23, 2014 | RX | Yes | No | 8,980,901 | ⤷ Subscribe | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL | ⤷ Subscribe | ||||
| Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-002 | Jul 23, 2014 | RX | Yes | Yes | 8,980,901 | ⤷ Subscribe | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,980,901
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1761540 | ⤷ Subscribe | PA2017004 | Lithuania | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | 300867 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | 122017000008 | Germany | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | CA 2017 00007 | Denmark | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | 1790006-9 | Sweden | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | 269 7-2017 | Slovakia | ⤷ Subscribe |
| European Patent Office | 1761540 | ⤷ Subscribe | C20170009 00226 | Estonia | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
